Who
Elizabeth M. Anderson
Director
Company insider
Files Form 4 as: Director, Revolution Medicines; Director, BioMarin Pharmaceutical; Director, Insmed.
In numbers
- Trades disclosed
- 60
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $7.3M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 6 Nov 2018
- Last trade
- 22 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $5,6785,070 at $1.12 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $175K910 at $191.85 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $960K4,985 at $192.54 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,070 at $0.00 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $512K2,648 at $193.44 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $292K1,500 at $194.59 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $20K100 at $195.15 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,070 at $0.00 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code M | $5,6785,070 at $1.12 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $175K910 at $191.85 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $960K4,985 at $192.54 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $512K2,648 at $193.44 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $292K1,500 at $194.59 | filing |
| 22 Sep 2026filed 24 Sep 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $20K100 at $195.15 | filing |
| 18 Jun 2026filed 23 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code A | —1,191 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,127 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,127 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code A | —1,191 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,490 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,490 at $0.00 | filing |
News
Revolution Medicines' Pancreatic Cancer Drug Gets Positive EU ReviewRVMD · finanzen.ch · 15 Oct 2026Revolution Medicines (NASDAQ:RVMD) Shares Up 3.4% on Analyst UpgradeRVMD · themarketsdaily.com · 14 Oct 2026Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' DaraxonrasibRVMD · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Elizabeth M. Anderson; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.